Torrent Pharma, on 23 October, announced its quarterly report for the July-September quarter.

The Pharma company reported a 23.7% year-on-year (YoY) growth in its net profit at Rs 386 crore for the quarter under review, from Rs 312 crore reported in the year-ago quarter.

The revenue from operations saw a 16% YoY increase to Rs 2,660 crore during the July-September quarter against Rs 2,291 crore reported in the same quarter of the previous fiscal year.

The pharma company revenue from the Indian operation saw an 18% YoY growth to Rs 1,444 crore on the back of double-digit growth in chronic therapies, traction in consumer demand, revival in gastro demand, and new launches.

The brazil operation saw an increase of 32% to Rs 252 crore during the July-September quarter, and revenue from German operations increased by 21% to Rs 266 crore, which was aided by new launches, growth in the generic segment, and the impact of sales spillover from the previous quarter of the same fiscal year.

However, the revenue from the US operations saw a dip by 15% YoY to Rs 248 crore, which was caused by low-margin business and a lack of new launches.

The EBITDA of the company for the quarter under review came to Rs 825 crore, with the EBITDA margins being at 32%.

As of 30 September, the company has 41 ANDAs (abbreviated new drug applications) that are awaiting approval with the USFDA (US Food and Drug Administration) and has received three tentative approvals during the quarter.